Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor …

C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …

Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy

M Sathekge, F Bruchertseifer, M Vorster… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …

Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding

C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

[HTML][HTML] 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

M Sathekge, F Bruchertseifer, O Knoesen… - European journal of …, 2019 - Springer
Background A remarkable therapeutic efficacy has been demonstrated with 225 Ac-prostate-
specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant …

mCRPC patients receiving 225Ac-PSMA-617 therapy in the post–androgen deprivation therapy setting: response to treatment and survival analysis

M Sathekge, F Bruchertseifer, M Vorster… - Journal of Nuclear …, 2022 - Soc Nuclear Med
225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is
overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in …

225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer

C Kratochwil, F Bruchertseifer, FL Giesel… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis

K Rahbar, M Schmidt, A Heinzel, E Eppard… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true
theranostic concept for diagnosis and therapy in patients with relapsed or metastatic …

[HTML][HTML] Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients

MP Yadav, S Ballal, RK Sahoo, M Tripathi, A Seth… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: Despite the success of several standards of care treatment options in metastatic
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …

[HTML][HTML] The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body …

J Maffey-Steffan, L Scarpa, A Svirydenka… - European journal of …, 2020 - Springer
Introduction A new therapeutic option for metastatic castration–resistant prostate cancer
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

F Khreish, N Ebert, M Ries, S Maus, F Rosar… - European journal of …, 2020 - Springer
Purpose Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive
metastatic castration-resistant prostate cancer (mCRPC) never respond or develop …